KeyPoints •EVT801 phase I study protocol has cleared third dose level and is recruiting well. •GBM AGILE pivotal study has opened in France, the fourth country to commence recruitment to the paxalisib arm. •Phase I study of paxalisib in combination withradiotherapy for treatment of brain metastases at Memorial Sloan Kettering Cancer Center has been accepted for presentation at an upcoming academic conferencein Q3 CY2022. •ATM financing facility has realized gross proceeds of US$2,956,036for the period ending June 2022, at an average price of $6.08(approximately AU$ 0.88 per share).
KZA Price at posting:
61.5¢ Sentiment: Buy Disclosure: Held